TMEM106A Inhibitors
PI3K inhibitors such as LY294002 and Wortmannin can decrease PI3K/Akt signaling, which is known to regulate membrane trafficking, a process that may directly affect the subcellular localization and function of TMEM106A. Inhibitors of the MAPK pathway, including SB203580 and U0126, act on different kinases within the pathway, potentially altering the expression and post-translational modification of TMEM106A. The proteasome inhibitor MG132 can lead to the buildup of ubiquitinated proteins, which may include TMEM106A if it is subject to ubiquitin-proteasome-mediated degradation.
Bafilomycin A1 and Rapamycin can interfere with lysosomal function and autophagy, respectively, both of which are critical for the turnover and processing of transmembrane proteins such as TMEM106A. SP600125 and PD98059, as inhibitors of JNK and MEK respectively, can modulate cellular stress responses and signaling pathways, impacting TMEM106A's role in these processes. The autophagy inhibitor 3-MA prevents the formation of autophagosomes, which could affect the degradation and recycling of TMEM106A. Cyclosporin A, as a calcineurin inhibitor, may impact calcium-dependent signaling pathways and thereby influence TMEM106A's function or expression. Lastly, Z-VAD-FMK, a pan-caspase inhibitor, can prevent apoptosis, a process in which TMEM106A may play a part.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibitor of PI3K, can lead to decreased PI3K/Akt signaling which is involved in regulating membrane trafficking and could thus influence TMEM106A localization or function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor, can alter inflammatory response and cellular stress pathways that might modulate TMEM106A expression or activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Proteasome inhibitor, can result in the accumulation of ubiquitinated proteins, possibly affecting the degradation of TMEM106A if it is a proteasome substrate. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
V-ATPase inhibitor, can disrupt lysosomal acidification, potentially impacting TMEM106A's lysosomal function or trafficking. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor, can lead to reduced ERK pathway signaling, which might affect TMEM106A expression levels or its post-translational modifications. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
Autophagy inhibitor, can prevent autophagosome formation, potentially affecting cellular turnover processes involving TMEM106A. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, can influence stress signaling pathways, potentially modulating TMEM106A's role in neuronal health or stress responses. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor, can lead to decreased ERK signaling potentially affecting TMEM106A function related to cell signaling and survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor, can modulate autophagy and lysosome biogenesis, processes that might affect TMEM106A's cellular localization or stability. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Irreversible PI3K inhibitor, can lead to decreased PI3K/Akt signaling which can influence TMEM106A's trafficking or degradation. | ||||||